These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
652 related articles for article (PubMed ID: 34804061)
1. Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds? Fei L; Ren X; Yu H; Zhan Y Front Immunol; 2021; 12():771210. PubMed ID: 34804061 [TBL] [Abstract][Full Text] [Related]
2. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds. Lança T; Costa MF; Gonçalves-Sousa N; Rei M; Grosso AR; Penido C; Silva-Santos B J Immunol; 2013 Jun; 190(12):6673-80. PubMed ID: 23686489 [TBL] [Abstract][Full Text] [Related]
3. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628 [TBL] [Abstract][Full Text] [Related]
4. CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments. Brummer G; Fang W; Smart C; Zinda B; Alissa N; Berkland C; Miller D; Cheng N Oncogene; 2020 Mar; 39(11):2275-2289. PubMed ID: 31827233 [TBL] [Abstract][Full Text] [Related]
5. CCR2-Dependent Recruitment of Tregs and Monocytes Following Radiotherapy Is Associated with TNFα-Mediated Resistance. Mondini M; Loyher PL; Hamon P; Gerbé de Thoré M; Laviron M; Berthelot K; Clémenson C; Salomon BL; Combadière C; Deutsch E; Boissonnas A Cancer Immunol Res; 2019 Mar; 7(3):376-387. PubMed ID: 30696630 [TBL] [Abstract][Full Text] [Related]
6. Roles of CCL2-CCR2 Axis in the Tumor Microenvironment. Kadomoto S; Izumi K; Mizokami A Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445235 [TBL] [Abstract][Full Text] [Related]
7. Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy. Ben-Yehuda H; Arad M; Peralta Ramos JM; Sharon E; Castellani G; Ferrera S; Cahalon L; Colaiuta SP; Salame TM; Schwartz M Mol Neurodegener; 2021 Jun; 16(1):39. PubMed ID: 34172073 [TBL] [Abstract][Full Text] [Related]
8. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Sanford DE; Belt BA; Panni RZ; Mayer A; Deshpande AD; Carpenter D; Mitchem JB; Plambeck-Suess SM; Worley LA; Goetz BD; Wang-Gillam A; Eberlein TJ; Denardo DG; Goedegebuure SP; Linehan DC Clin Cancer Res; 2013 Jul; 19(13):3404-15. PubMed ID: 23653148 [TBL] [Abstract][Full Text] [Related]
9. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2 Takacs GP; Kreiger CJ; Luo D; Tian G; Garcia JS; Deleyrolle LP; Mitchell DA; Harrison JK Front Immunol; 2022; 13():993444. PubMed ID: 36685592 [TBL] [Abstract][Full Text] [Related]
10. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Huang B; Lei Z; Zhao J; Gong W; Liu J; Chen Z; Liu Y; Li D; Yuan Y; Zhang GM; Feng ZH Cancer Lett; 2007 Jul; 252(1):86-92. PubMed ID: 17257744 [TBL] [Abstract][Full Text] [Related]
11. Recruitment of γδ T cells to the lesion via the CCL2/CCR2 signaling after spinal cord injury. Xu P; Zhang F; Chang MM; Zhong C; Sun CH; Zhu HR; Yao JC; Li ZZ; Li ST; Zhang WC; Sun GD J Neuroinflammation; 2021 Mar; 18(1):64. PubMed ID: 33653377 [TBL] [Abstract][Full Text] [Related]
12. Role of CCL2/CCR2 axis in the immunopathogenesis of rheumatoid arthritis: Latest evidence and therapeutic approaches. Moadab F; Khorramdelazad H; Abbasifard M Life Sci; 2021 Mar; 269():119034. PubMed ID: 33453247 [TBL] [Abstract][Full Text] [Related]
14. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345 [TBL] [Abstract][Full Text] [Related]
15. Is the C-C Motif Ligand 2-C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis? Iwamoto H; Izumi K; Mizokami A Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297571 [TBL] [Abstract][Full Text] [Related]
16. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760 [TBL] [Abstract][Full Text] [Related]
17. Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting. Xu M; Wang Y; Xia R; Wei Y; Wei X Cell Prolif; 2021 Oct; 54(10):e13115. PubMed ID: 34464477 [TBL] [Abstract][Full Text] [Related]
18. Monocytic myeloid-derived suppressor cells home to tumor-draining lymph nodes via CCR2 and locally modulate the immune response. Lahmar Q; Schouppe E; Morias Y; Van Overmeire E; De Baetselier P; Movahedi K; Laoui D; Sarukhan A; Van Ginderachter JA Cell Immunol; 2021 Apr; 362():104296. PubMed ID: 33556903 [TBL] [Abstract][Full Text] [Related]
19. CCL3/CCR1 mediates CD14 Zhao X; Gu M; Xu X; Wen X; Yang G; Li L; Sheng P; Meng F Osteoarthritis Cartilage; 2020 May; 28(5):613-625. PubMed ID: 32006659 [TBL] [Abstract][Full Text] [Related]
20. Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis. Izhak L; Wildbaum G; Jung S; Stein A; Shaked Y; Karin N PLoS One; 2012; 7(1):e28305. PubMed ID: 22279523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]